Sheena Smith
Assistant Professor of Biotechnology, School of Chemistry, Chemical Engineering and Biotechnology (CCEB), Nanyang Technological University, Singapore
Sheena Smith is listed as Assistant Professor of Biotechnology, School of Chemistry, Chemical Engineering and Biotechnology (CCEB), Nanyang Technological University, Singapore. Sheena is scheduled to speak at Advanced Therapies Week 2027 on 21 January 2027.
Compiled from published conference agendas; not yet confirmed by Sheena. Is this you? Claim this profile.
About
Dr. Sheena N. Smith is an Assistant Professor of Biotechnology at Nanyang Technological University Singapore where she leads an academic group in engineering next-generation gene therapy vectors for precision in vivo delivery. Her research integrates protein engineering and synthetic biology to create programmable virus-like particles (VLPs) for oncology and neurological diseases. She is a co-inventor of SHREAD (SHielded, REtargeted ADenovirus), a modular system for targeted delivery and in situ production of therapeutic biologics. Before returning to academia, she was a founding executive at Swiss biotechnology company where she helped translate SHREAD from academic discovery into an industrial therapeutic platform. She earned her PhD in Biochemistry from the University of Illinois Urbana-Champaign, and completed her postdoctoral training at the University
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel discussion Speaker · 21 January 2027
- Session 8: How and where is innovation in both systemic and local delivery enabling the migration of advanced therapies into emerging indications and therapeutic areas? Speaker · 21 January 2027
- Session 9: Next-generation vector systems and emerging payloads – how and where can they enable the cell & gene therapy field to advance? Speaker · 21 January 2027
- Spotlight: Engineering precision in vivo delivery with SHREAD adenoviral VLPs Speaker · 21 January 2027
Spoke alongside
People who have shared a session with Sheena at events on B2DB.
- Jeroen de Vrij CEO · ExoVectory 1 shared session
- Mercedes Segura Gally VP Process Development · Editas Medicine 1 shared session
- Michael Klichinsky CSO · Nava Therapeutics 1 shared session
- Nathalie Clément Senior Vice President, Vector Development · Siren Biotechnology 1 shared session